Navidea biopharmaceuticals announces acceptance of abstract for presentation at upcoming society for immunotherapy of cancer annual meeting

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that results from the company's ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the manocept platform have been accepted for presentation at the 37th annual meeting of the society for immunotherapy of cancer (“sitc”) to be held at the
NAVB Ratings Summary
NAVB Quant Ranking